VHL and renal cell adenocarcinoma: The exponential growth of research on RCC has led to the clinical knowledge that RCC has mutated pathways like the VHL pathway that sustains RCC cell growth by supporting angiogenesis, and the PI3K-Akt-mTOR pathway that supports the progression of the disease (24).